Outcomes of Patients With Nasopharyngeal Plasmacytoma: A Systematic Review

Omar Ramadan, PhD

Independent Researcher, Paterson, NJ 07533, USA

ABSTRACT

Background: This study reviews the published literature related to nasopharyngeal plasmacytoma. Clinical presentation, demographics, treatment, and outcomes of this uncommon disease have been reported.

Methods: A systematic review of studies on nasopharyngeal plasmacytoma from 1935 to 2016 was conducted. A PubMed database search was performed for articles related to this condition along with the bibliographies of those selected articles. Articles were examined for patient data that reported the disease outcome.

Results: Fifty-eight journal articles were included in this analysis, comprising of a total of 114 studies indicative of a predilection for cases particularly in men with a mean age of 55 years (sixth decade of life) characterized with symptoms such as nasal obstruction, epistaxis and neck lymphadenopathy. Radiotherapy was the most common treatment modality, followed by a combination of surgery and radiotherapy. Most of the patients were alive with no evidence of the disease after the median follow-up of 59 months. Of the 3 most common treatment modalities, a combination of radiotherapy and surgery had the most favorable outcome for a majority of patients. The existing condition for 8 patients (7%) deteriorated leading to the development of multiple myeloma.

Conclusion: This review contains a large pool of information about nasopharyngeal plasmacytoma patients examined to date suggesting that aggressive radiotherapy is the most common treatment modality for this condition. Of the 3 most common treatment modalities, a combination of surgery and radiotherapy was shown to have the best survival outcomes.

KEY WORDS: Pharyngeal plasmacytoma; Extramedullary plasmacytoma; Nasopharyngeal tumor; plasmacytoma; Radiotherapy; Chemotherapy; Surgical management.

ABBREVIATIONS: EMP: Extramedullary plasmacytoma; MM: Microcystic Meningioma; OS Overall Survival; DSS: Disease-specific survival; DOD: Died of Disease; ANED: Alive with no evidence of disease; AWD: Alive with disease.

INTRODUCTION

Extramedullary plasmacytoma (EMP) is an uncommon tumor, constituting only 3% of all plasma cell neoplasms and less than 1% of all head and neck tumors. Nasopharyngeal plasmacytomas are very rare tumors with very few cases reported in the literature. Thus, there is little evidence regarding the epidemiology, optimal management, and long-term prognosis for these types of cancers. Because it is an uncommon tumor, it is difficult to perform a randomized controlled trial to determine the optimal management of nasopharyngeal EMPs. Therefore, in this article; we perform a systematic review of 114 cases of nasopharyngeal EMPs, representing the largest unified collection of nasopharyngeal EMPs investigated to date.

Our goal was to analyze the demographics, presentation symptoms, treatment modalities, prognosis, recurrence, and microcystic meningioma (MM) development of this rare form of tumor.
MATERIALS AND METHODS

Search Strategy

A systematic review was conducted for all cases of nasopharyngeal plasmacytoma reported from 1935 to 2016 using the PubMed database. The search criteria were set as “nasopharyngeal plasmacytoma,” “head and neck plasmacytoma,” “upper airways plasmacytoma,” and “sinonasal plasmacytoma”. Four hundred eighty-one articles were initially analyzed. Articles were then filtered to exclude studies conducted in non-human subjects and non-English articles.

Abstracts were first reviewed to search for articles that discussed cases of plasmacytoma occurring in the nasopharynx and full-text articles were subsequently selected and reviewed for data extraction. References of the included studies were examined for additional cases (Figure 1).

Selection Criteria and Data Extraction

All studies conducted on human subjects and published in English language that reported individual data for nasopharyngeal plasmacytoma were included if they reported diagnosis, treatment, follow-up, and outcome. Non-human, radiologic, cadaveric, anatomical, and histological studies were excluded, on account of being sources with insufficient or unextractable data. Articles with unobtainable full text were also excluded from the study. Outcome measures extracted included: demographic data, presenting symptoms, primary treatment modality, recurrence, MM development and metastasis.

Two-year overall survival (OS), disease-specific survival (DSS), locoregional recurrence and MM development rates were calculated using the Kaplan-Meier method. Differences in the survival rates were assessed by the log-rank test. All the recorded p-values were two-sided, and a p-value <0.05 was adopted as the threshold for statistical significance.

RESULTS

The final PubMed searches using the selected keywords yielded 58 studies from a total of 114 patients which were left for statistical analysis. All 58 studies included individual patient data that was extractable and fit the minimum criteria for inclusion (Table 1).

Demographics

Patient demographics for 113 patients included in this review are summarized in Table 2.

The mean age of patients was 55 years, ranging from 3 to 85 years. Males constituted nearly 69.4% of the cases, whereas females constituted nearly 30.6% of the cases. The mean follow-up for patients was 59 months. Information about histological grade was reported in only 19 articles. The most common presenting symptom was nasal obstruction (29.8% of cases). Further demographic information is summarized in Table 2.

Treatment Modalities and Outcome

A majority of patients nearly 56% were treated with radiotherapy alone (n=63) and nearly 21% were treated in combination with surgery, or in combination with surgery and chemotherapy (n=3), or in combination with chemotherapy (n=4). The remaining patients received surgery alone (n=13) or chemotherapy alone (n=1). Further information regarding treatment modality
| Article       | Age/Sex | S/M | Symptom                  | Path | LN | R/x | LRC | DM | Outcomes     |
|--------------|---------|-----|--------------------------|------|----|-----|-----|----|--------------|
| Fu et al     | 68/M    | S   | Nasal obstruction       | N/A  | -  | S   | -   | -  | NED 3 M      |
|              | 35/M    | S   | Nasal obstruction       | N/A  | -  | S   | -   | -  | NED 1 M      |
| Poole et al  | 51/M    | M   | Nasal obstruction foreign body sensation | N/A  | -  | S+RT | -   | -  | Dead 4 Y     |
|              | 41/M    | M   | Epistaxis               | N/A  | -  | S+RT | -   | -  | Dead 5 Y     |
|              | 78/M    | S   | Nasal obstruction epistaxis | N/A  | -  | S+RT | -   | -  | NED 7 Y      |
|              | 59/F    | S   | Nasal obstruction epistaxis | N/A  | -  | RT  | -   | -  | NED 8 Y      |
| Lindberg et al | 65/M  | S   | Nasal obstruction epistaxis | N/A  | -  | RT  | -   | -  | NED 10 Y     |
| Bush et al   | 41/M    | S   | N/A                      | N/A  | -  | RT  | * local | + femur | On chemotherapy 7.5 year | NED 18 M |
|              | 56/M    | S   | N/A                      | N/A  | -  | RT  | -   | -  | MM 2 Y Dead 9 Y |
| Kapedia et al | 45/M   | S   | N/A                      | N/A  | -  | RT  | -   | -  | N/A          |
|              | 78/M    | S   | N/A                      | N/A  | -  | RT  | -   | -  | N/A          |
|              | 52/M    | S   | N/A                      | N/A  | -  | RT+ CH | - | Other back of tibia | MM 2 M Dead MM 14 M |
| Du et al     | 63/M    | S   | Nasal obstruction epistaxis 6 cranial nerve palsy | N/A  | -  | RT  | -   | -  | NED 18 M     |
| Stout et al  | 61/F    | s   | Nasal obstruction       | N/A  | -  | RT  | -   | + femur | Dead from metastasis 3.5 Y |
|              | 38/M    | s   | Post nasal discharge    | N/A  | -  | S+RT | -   | -  | NED 2 Y      |
| Figi et al   | 48/M    | s   | N/A                      | N/A  | -  | S+RT | -   | -  | NED 3 Y      |
|              | 47/F    | s   | N/A                      | N/A  | -  | S+RT | -   | -  | AWD 20       |
| Scuderi et al | 39/M   | s   | N/A                      | N/A  | -  | S+RT | -   | -  | NED 6 M      |
| Mattick et al | 61/M   | M   | N/A                      | N/A  | -  | S   | -   | -  | NED 3 M      |
| Ewing et al  | 61/M    | S   | N/A                      | N/A  | -  | RT  | -   | -  | N/A          |
|              | 48/F    | S   | Hearing loss             | N/A  | -  | RT  | -   | -  | Dead of stomach cancer 3 Y |
|              | 48/M    | S   | Accidentally             | N/A  | -  | S   | -   | -  | NED 22 Y     |
|              | 83/F    | S   | Epistaxis                | N/A  | -  | RT  | -   | + | Another Solitary Ankle | Dead 1 Y metastasis |
|              | 49/M    | S   | Nasal obstruction       | N/A  | -  | RT  | -   |   | Lymph node 7 year removed +RT | NED 7 Y |
|              | 76/M    | S   | Nasal obstruction       | N/A  | +  | RT  | -   | -  | Dead 6 M      |
| Waltner et al | 39/M   | S   | Nasal obstruction       | N/A  | -  | RT  | -   | -  | NED 2 Y      |
|              | 61/F    | S   | N/V                      | N/A  | -  | RT  | -   | + | Dead 6 Y metastasis |
| Anderson et al | 39/M  | S   | Nasal obstruction       | N/A  | +  | RT  | Local 1 year | + 1 Y | Dead 1 YEAR metastasis |
|              | 72/M    | S   | Nasal obstruction       | N/A  | -  | S+RT | -   | -  | NED 5 Y      |
|              | 77/F    | S   | Nasal obstruction       | N/A  | +  | RT  | -   | -  | Dead 7 M      |
| Name          | Age | Gender | Symptom      | Treatment | Outcome 1 | Outcome 2 | Outcome 3 |
|--------------|-----|--------|--------------|-----------|-----------|-----------|-----------|
| Fuerste et al | M/56| S      | N/A          | N/A       | +         | NED 2 Y  |           |
| Dolin et al  | M/66| S      | N/A          | S+RT      | -         | AWD 2 Y  |           |
| Mann et al   | M/3 | S      | N/A          | S         | -         | NED 1 Y  |           |
| Tan et al    | F/12| S      | N/A          | S+RT      | -         | NED 1 Y  |           |
| Rutherford et al | M/43 | MM | N/A          | RT        | -         | NED 19.5 Y |           |
| Fuerste et al | M/66| S      | N/A          | S+RT      | -         | NED 1 Y  |           |
| Corwin et al | 54/M| S      | N/A          | RT        | -         | NED 320 M |           |
| Wiltshaw et al | F/21 | S | N/A          | RT+Ch     | -         | NED 8 Y  |           |
| Ching et al  | F/66| S      | N/A          | RT        | -         | NED 1 Y  |           |
| Zou et al    | M/45| S      | N/A          | S         | -         | N/A      |           |
| Khademi et al | F/66 | S | N/A          | S+RT      | -         | NED 32 M |           |
| Susnerwala et al | M/72 | S | N/A          | k         | RT        | Dead 48 M from MI |           |
| Wein et al  | M/48| S      | N/A          | RT        | -         | NED 44 M |           |
| Manganaris et al | M/41 | S | Epistaxis    | N/A       | S         | NED 2 Y  |           |
| Chang et al  | M/15| S      | Epistaxis    | S+RT      | -         | NED 3 M  |           |
| Abdullah et al | 64/F | S | Epistaxis    | S+RT      | -         | NED 6 M  |           |
| Lin et al    | 42/M| S      | Nasal Obstruction | N/V | RT  | N/A |           |
| Azman et al  | M/56| S      | Epistaxis    | S+RT      | -         | NED 7 Y  |           |
| Natt et al   | M/75| S      | Epistaxis    | RT        | -         | NED 6 M  |           |
| Sulzner et al | M/56 | S | Epistaxis    | RT        | -         | Dead 6 Y of MI |           |
| Name            | Age Gender | Site          | Stage | Treatment | Recurrence | Survival Time |
|-----------------|------------|---------------|-------|-----------|------------|----------------|
| Knowlin et al.  | M/79       | N/A           | N/A   | RT        | -          | Dead 100 M of COPD |
| Sadek et al.    | M/48       | Epistaxis nasal obstruction | K     | RT + S + Ch | +          | NED 12 Y       |
| Woodruff et al. | M/20       | N/A Invasive  | N/A   | RT + CH   | RE 3 M     | DEAD 6 Y of disease |
| M/77            | S          | N/A           | N/A   | RT        | -          | DEAD 3 M MI    |
| M/56            | S          | N/A Invasive  | N/A   | + RT      | -          | DEAD 16 Y      |
| Chao et al.     | M/69       | E             | N/A   | RT        | -          | MM 9 M, DEAF 11 M |
| M/74            | S          | Nasal obstruction | N/A   | - RT      | -          | NED 68 M       |
| Nikolidakis et al | F/72      | Hearing loss nasal obstruction | K     | RT + S    | -          | NED 2 Y        |
| Hotz et al.     | M/63       | N/A           | N/A   | RT + S    | -          | NED 108 M      |
| M/77            | S          | N/A           | N/A   | RT + S    | -          | AWD 18 M       |
| M/59            | S          | N/A           | N/A   | RT + S    | -          | NED 157 M      |
| M/44            | S          | N/A           | N/A   | - S       | -          | N/A            |
| M/45            | M          | N/A           | N/A   | RT + S    | -          | AWD 108 M      |
| M/43            | S          | N/A           | N/A   | RT + S    | -          | AWD MM 116 M   |
| Kolner et al.   | M/59       | N/A           | N/A   | RT        | Recurrent 1 year then RT | NED 8 Y |
| M/49            | S          | N/A           | N/A   | RT        | Recurrent then RT | NED 9 Y |
| M/60            | S          | N/A           | N/A   | RT        | -          | NED 1 M        |
| M/64            | S          | N/A Invasive  | N/A   | RT        | -          | MM 6 M, DEAD 6 M |
| M/78            | S          | N/A           | N/A   | - S       | -          | Dead 6 M MI    |
| M/72            | S          | Nasal obstruction invasive | N/A   | none      | -          | Dead 6 M       |
| Miller et al.   | M/76       | Nasal obstruction | k     | RT 56     | -          | NED 26 M       |
| M/64            | S          | Nasal obstruction | I     | RT 64     | -          | NED 36 M       |
| M/49            | S          | Nasal obstruction headache | N/V   | RT 48 Gy  | -          | NED 131 M      |
| F/20            | S          | Nasal obstruction | N/A   | RT 46 Gy  | -          | NED 120 M      |
| M/47            | S          | Hearing Loss   | K     | RT 60 Gy  | Local recurrence 1 year Treated with surgery | NED 28 M |
| M/63            | S          | Nasal obstruction | K     | RT 25     | -          | NED 27 M       |
| Isri et al.     | F/49       | Nasal obstruction | N/A   | RT + ch + S | -          | NED 2 Y        |
| Widziszowska et al | M/63     | Nasal obstruction epistaxis invasive | N/A   | RT + ch + S | Recurrent 6 month | AWD 6 M |
| Satomi et al.   | M/72       | Epistaxis      | L     | RT + ch + S | -          | NED 2 Y        |
| Lorusso et al.  | M/71       | Hearing loss epistaxis | K     | S         | -          | NED 4 M        |
| Shih et al.     | M/49       | N/V            | N/A   | RT        | Recurrent 9 years | AWD 131 M |
| M/28            | S          | Mass           | N/A   | + RT + CH | -          | NED 2 Y        |
| M/62            | S          | Mass           | N/V   | + RT      | -          | NED 95 M       |
| M/64            | S          | Mass           | N/V   | + CH      | CH         | MM 64 M, AWD 97 M |
is summarized in Table 3.

Patient outcomes in this study were classified as either alive with no evidence of disease (ANED), alive with disease (AWD), died of disease (DOD), and died not of disease (D). The overall outcome was favorable, as 67 patients (57.5%) were alive with no evidence of the disease and 11 patients (14.3%) were alive with the disease after a median follow-up of 59 months. A total of 26 patients (27.4%) died, such that 15 of these patients (13.8%) were dying due to the disease. Table 2 details patient outcomes by treatment modality.

Considering the entire cohort, the 2-year and 5-year rates of overall survival were 87.5% and 82.6%, respectively; the rates of DSS were 92.6% and 90%, respectively; the rates of locoregional recurrence were 79.3% and 78.1%, respectively; and the rates of MM or distant metastasis development were 88.4% and 85.8%, respectively.

Using Kaplan-Meier log rank test; a combination of radiotherapy and surgery had the most favorable overall survival outcomes.

**DISCUSSION**

The overall annual incidence of plasma cell tumors is 3:100,000. Plasma cell tumors are classified into three subtypes. Multiple myeloma is the most common type, bone solitary plasmacytoma, and soft tissue EMP being considerably less common (Table 4). Genetic factors, smoking, chronic antigenic stimulation such as osteomyelitis, radiation exposure, and occupational exposures have also been reported as possible etiologic agents in the literature. Wiltshaw et al reported that 80% of extramedullary plasmacytomas occur in the head and neck region, and 40% of them occur in the nasal cavity and paranasal sinus, 20% in the nasopharynx, and 18% in the oropharynx. Cervical lymph node
Table 2: Characteristics.

| Cases, n | 114 |
|-----------------|-----|
| Demographics   |     |
| Age, years, mean (range) | 55 (3-85) |
| Gender          |     |
| Male            | 79 (69%) |
| Female          | 23 (20%) |
| Unknown         | 12 (11%) |
| Presenting symptoms in only 56 article | |
| Obstruction     | 36 (64%) |
| Epistaxis       | 19 (33%) |
| Hearing loss    | 4 (7%) |
| Nasal discharge | 1 (2%) |
| CN VI palsy     | 1 (2%) |
| Headache        | 2 (3%) |
| Foreign body sensation | 4 (6%) |
| Neck mass       | 10 (18%) |
| Dysphagia, anosmia | 3 (5%) |
| Associated with other solitary myeloma Multiple | 11 (9%) |
| Pathology 19 article | |
| Kappa           | 13/19 |
| Lambda          | 6/19 |
| Follow-up, months, mean; median (range) only 106 article | 59.6 (1-336) |
| Outcome         |     |
| NED             | 67 (59%) |
| AWD             | 11 (10%) |
| DOD             | 15 (13%) |
| D               | 13 (11%) |
| N/A             | 8 (7%) |
| Follow-up measures | |
| Loco-regional recurrence | 20 (17%) |
| Multiple myeloma | 8 (7%) |
| Metastasis      | 109% |

NED: No evidence of disease; AWD: Alive with disease; DOD: Dead of the disease; D: Dead of other causes; N/A: Non-Available.

Table 3: Treatment Modalities.

| Treatment                          | Cases (n)% |
|-----------------------------------|------------|
| Radiotherapy alone                | 64 (56%)   |
| Surgery alone                     | 13 (11%)   |
| Chemotherapy alone                | 1 (1%)     |
| Surgery and radiotherapy          | 25 (21%)   |
| Radiotherapy and chemotherapy     | 5 (3%)     |
| Radiotherapy, surgery, and chemotherapy | 3 (2%)   |
| None                              | 3 (2%)     |

metastasis is reported as initial presentation in 12-26% of the cases, and about 20% of the EMP cases have multiple lesions. The EMP stages can be identified according to the spread of the disease (Table 5).24

Head and neck plasmacytoma tend to occur more frequently in males (male: female ratio, 3:1) during the 5th and 7th decades of life, however, it is rarely diagnosed in younger patients.60
Nasopharyngeal EMP was first reported by Kusunoki in 1915, of which about 20% of the head and neck plasmacytomas occur in the nasopharynx. (Table 4). Patel et al. identified 778 patients with EMP in the head and neck region, 137 of them reportedly have plasmacytoma in the nasopharynx. D’Aguillo et al. reported 176 cases of sinonasal extramedullary plasmacytoma, of which 36 cases were associated with the nasopharynx (Table 6).

The common symptoms of nasopharyngeal EMP include nasal obstruction, epistaxis, and conductive hearing loss. On performing nasal endoscopic examination, the lesions usually grow sub-mucosally as soft gray sessile or pedunculated masses, which can rarely be ulcerated. The diagnosis of EMP is done by tissue biopsy. Deep biopsies must be performed since the tumor is located in the submucosal layer and the mucosa may be thickened due to an inflammatory reaction. Once the diagnosis has been confirmed, further investigations are required to exclude multiple myeloma. Three histological subtypes of plasmacytoma have been reported including plasmacytic, plasmablastic and anaplastic subtypes. However, these subtypes are not indicative of prognosis or increased risk of recurrence. Local amyloid deposits may be found in 11-38% of the cases reported but systemic amyloidosis is a rare occurrence. Immunohistochemical techniques may indicate a monoclonal staining pattern for heavy chain class, light chain class tumor or both. CD 138 has been reported as a gold marker for plasma cell tumor.

Complete surgical resection (if possible) with postoperative radiotherapy is the treatment of choice for solitary EMP. In general, EMPs are considered radiosensitive, with a local control rate of 90-100%. A radiation dose of 4050 Gy delivered to the primary site of the EMP in the nasopharynx is usually recommended. Since EMP is highly radiosensitive with a local control rate of 90%, there is no evidence as to whether radiotherapy should also be targeted against cervical lymph nodes, in order to decrease the risk of local and regional recurrence. Chemotherapy is generally recommended for recurrent, advanced, or disseminated disease.

Nasopharyngeal extramedullary plasmacytoma has a good prognosis but also requires a long-term follow-up to detect any local recurrence or progression towards multiple myeloma.
CONCLUSION

This review contains the largest pool of data collected from nasopharyngeal EMP patients examined till date. Our data suggests that radiotherapy alone is the most common type of treatment used, followed by a combination of radiotherapy and surgery, then surgery alone. A combination of radiotherapy and surgery showed the best outcomes in patients in terms of survival and eradication of the disease; however, this subgroup consisted of only 25 patients. MM developments occurred in 7% of the patients.

Most of the data included in this study was collected from case reports and case series. Further research on the optimal treatment modality, should be done using randomized controlled clinical trials to ensure less bias and better accuracy of results.

CONFLICTS OF INTEREST

The author declared no conflict of interest.

REFERENCES

1. Fu YS, Perzin KH. Nonepithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx. A clinicopathologic study. VI. Fibrous tissue tumors (fibroma, fibromatosis, fibrosarcoma). Cancer. 1976; 37(6): 2912-2928. doi: 10.1002/1097-0142(197606)37:6<2912::AID-CNCR282070649>3.0.CO;2-L

2. Poole AG, Marchetta FC. Extramedullary plasmacytoma of the head and neck. Cancer. 1968; 22(1): 14-21. doi: 10.1002/1097-0142(196807)22:1<14::AID-CNCR282020104>3.0.CO;2-P

3. Lindberg R. Unusual malignant tumors of the head and neck. Radiology. 1966; 86: 1090-1095. doi: 10.1148/86.6.1090

4. Bush SE, Goffinet DR, Bagshaw MA. Extramedullary plasmacytoma of the head and neck. Radiology. 1981; 140(3): 801-805. doi: 10.1148/radiology.140.3.6792654

5. Kapadia SB, Desai U, Cheng VS. Extramedullary plasmacytoma of the head and neck: A clinicopathologic study of 20 cases. Medicine (Baltimore). 1982; 61(5): 317-329. Web site. http://journals.lww.com/md-journal/Citation/1982/09000/Extramedullary_Plasmacytoma_of_the_Head_and_Neck_4.aspx. Accessed February 17, 2017.

6. Du RC, Li HN, Huang W, Tian XY, Li Z. Unusual coexistence of extramedullary plasmacytoma and nasopharyngeal carcinoma in nasopharynx. Diagn Pathol. 2015. 17; 10:170. doi: 10.1186/s13000-015-0405-y

7. Stout AP, Kenney FR. Primary plasma-cell tumors of the upper air passages and oral cavity. Cancer. 1949; 2(2): 261-278. doi: 10.1002/1097-0142(194903)2:2<261::AID-CNCR2820020206>3.0.CO;2-K

8. Figi FA, Broders AC, and Havens FZ. Plasma cell tumors of the upper part of the respiratory tract. Ann Otol Rhin Laryng. 1945; 54: 283-297. doi: 10.1158/aje.1935.513

9. Mattick WL, Thibaudeau AA. Extramedullary Plasma-cell tumors of the upper air passages: With report of a case. Am J Cancer. 1935; 23: 513-521. doi: 10.1158/aje.1935.513

10. Scuder R. Contributo allo studio dei tumori plasmocitari delle prime vie aeree [In Italian]. Tumori. 1942; 16: 13-28.

11. Ewing MR, Foote FW Jr. Plasma-cell tumors of the mouth and upper air passages. Cancer. 1952; 5(3): 499-513. doi: 10.1002/1097-0142(195205)5:3<499::AID-CNCR2820050310>3.0.CO;2-V

12. Webb HE, Harrison EG, Masson JK, Remine WH. Solitary extramedullary myeloma (plasmacytoma) of the upper part of the respiratory tract and oropharynx. Cancer. 1962 ;15: 1142-1155. doi: 10.1002/1097-0142(196211/12)15:6<1142::AID-CNCR2820150610>3.0.CO;2-5

13. Waltner JG. Plasma cell tumors of the nasopharynx. Ann Otol Rhinol Laryngol. 1947; 56(4): 911-916. doi: 10.1177/000348944705600406

14. Anderson E. Extramedullary plasmacytomas. Actaradiol. 1949; 32: 365-374.

15. Fuerste F, Zuckerman SS. Extramedullary plasma cell tumor. Arch Otolaryng. 1950; 51: 608-615. doi: 10.1001/archotol.1950.00700020631011

16. Dolin S, Dewar JP. Extramedullary plasmacytoma. Am J Pathol. 1956; 32(1): 83-103.

17. Mann G, Trebo MM, Minkov M, Simonitsch I, Chott A, Gaddner H. Extramedullary plasmacytoma of the adenoids. Pediatr Blood Cancer. 2007; 48(3): 361-362. doi: 10.1002/pbc.20547

18. Tan CL, Tan SH, Ng SB, Petersson F. Expect the unexpected: Report of a case of pediatric pharyngeal extrasosseous plasmacytoma with tumefactive amyloidosis (“Amyloidoma”) and a review of the literature. Head Neck Pathol. 2015; 9(4): 431-435. doi: 10.1007/s12105-015-0614-4

19. Rutherford K, Parsons S, Cordes S. Extramedullary plasmacytoma of the larynx in an adolescent: A case report and review of the literature. Ear Nose Throat J. 2009; 88: E1-E7.

20. Strojan P, Soba E, Lamovec J, Munda A. Extramedullary-plasmacytoma: Clinical and histopathologic study. Int J Radiat Oncol Biol Phys. 2002; 53(3): 692-701. doi: 10.1016/S0360-
23. Wiltshaw E. Chemotherapy in the management of extramedullary plasmacytoma. Cancer Chemother Pharmacol. 1978; 1(3): 167-175. doi: 10.1007/BF00253117

24. Ching AS, Khoo JB, Chong VF. CT and MR imaging of solitary extramedullary plasmacytoma of the nasal tract. AJNR Am J Neuroradiol. 2002; 23(10): 1632-1636. Web site. http://www.ajnr.org/content/23/10/1632.long. Accessed February 17, 2017.

25. Zuo Z, Tang Y, Bi CF, et al. Extraosseous (extramedullary) plasmacytomas: A clinicopathologic and immunophenotypic study of 32 Chinese cases. Diagnostic Pathology. 2011; 6: 123. doi: 10.1186/1746-1596-6-123

26. Khademi B, Zandifar Z, Mohammadianpanah M, et al. Head and neck solitary extramedullary plasmacytoma. Journal of Oral Oncology. 2014; 2014: 238698. doi: 10.1155/2014/238698

27. Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ. Extramedullary plasmacytoma of the head and neck region: Clinicopathological correlation in 25 cases. Br J Cancer. 1997; 75(6): 921-927.

28. Wein RO, Popat SR, Doerr TD, Dutcher PO. Plasma cell tumors of the skull base: Four case reports and literature review. Skull Base. 2002; 12(2): 77-86.

29. Manganaris A, Conn B, Connor S, Simo R. Uncommon presentation of nasopharyngeal extramedullary plasmacytoma: A case report and literature review. B-ENT. 2010; 6(2): 143-146. Web site. http://europepmc.org/abstract/med/20681370. Accessed February 17, 2017.

30. Chang YL, Chen PY, Hung SH. Extramedullary plasmacytoma of the nasopharynx: A case report and review of the literature. Oncol Lett. 2014; 7(2): 458-460. doi: 10.3892/ol.2013.1712

31. Abdullah AM, Ibrahim Z, Yusuf Z, Ramli RR. An extramedullary plasmacytoma of the nasopharynx: A rare entity: Case report. Bangladesh Journal of Medical Science. 2016; 15(3): 477-479. doi: 10.3329/bjms.v15i3.21959

32. Yuan-Yung Lin, Li-Hsiang Cheng, Yaoh-Shiang Lin, Bork-Hwang Kang. Extramedullary plasmacytoma of the Nasopharynx. J Med Sci. 2010; 30(5): 211-213. Web site. http://oldjms.ndmctsgh.edu.tw/db/File/3005211.pdf. Accessed February 17, 2017.

33. Azman M, Gendeh BS, Mat Ali SA. Extramedullary plasmacytoma of the nasopharynx: A rare tumour with 7-year follow up. Philipp J Otolaryngol Head Neck Surg. 2011; 26 (1): 27-30. Web site. http://apamedcentral.org/Synapse/Data/PDFData/0011PJOHNS/pjohns-26-27.pdf. Accessed February 17, 2017.
BG. Plasmacytomas of the head and neck. *Otolaryngol Head Neck Surg.* 1998; 119(6): 614-618. doi: 10.1016/S0194-5988(98)70021-X

44. Satomi F, Kohmoto E, Okamoto R, Morisaki Y, Ono K, Kumoi T. A solitary extramedullary plasmacytoma of the nasopharynx. *Gan No Rinsho.* 1990; 36(5): 629-635. Web site. http://europepmc.org/abstract/med/2109136. Accessed February 17, 2017.

45. Iseri M, Ozturk M, Ulubil SA. Synchronous presentation of extramedullary plasmacytoma in the nasopharynx and the larynx. *Ear Nose Throat J.* 2004; 83(10): 673-674.

46. Lorusso GD, Palacios E, Sarma DP. Plasmacytoma of the nasopharynx. *Otolaryngol Pol.* 2008; 62(4): 483-485. doi: 10.1016/S0030-Otolaryngol Head Neck Surg. 1998; 119(6): 614-618. doi: 10.1016/S0030-0022/15100077732

47. Lorusso GD, Palacios E, Sarma DP. Plasmacytoma of the nasopharynx. *Ear Nose Throat J.* 2004; 83(10): 673-674. Web site. https://www.researchgate.net/profile/Deba_Sarma/publication/8140885_Plasmacytoma_of_the_nasopharynx/links/0889ac53b26ae9295744ad61.pdf. Accessed February 17, 2017.

48. Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN. Localisedplasmacytomas in Taiwan: Comparison between extramedullaryplasmacytoma and solitary plasmacytoma of bone. *Br J Cancer.* 1995; 71(1): 128-133.

49. Yavas O, Altundag K, Sungur A. Extramedullary plasmacytoma of the nasopharynx and larynx: Synchronous presentation. *Am J Hematol.* 2004; 75(4): 264-265. doi: 10.1002/ajh.20038

50. Mayr NA, Wen BC, Hussey DH, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. *Radiother Oncol.* 1990; 17(4): 293-303. doi: 10.1016/0167-8140(90)90003-F

51. Petrovitch Z, Fishkin B, Hittle RE, Acquarelli M, Barton R. Extramedullary plasmacytoma of the upper respiratory passageways. *Int J Radiat Oncol Biol Phys.* 1977; 2(7-8): 723-730. doi: 10.1016/0360-3016(77)90054-2

52. Abemayor E, Canalis RF, Greenberg P, Wortham DG, Rowland JP, Sun NC. Plasma cell tumors of the head and neck. *J Otolaryngol.* 1988; 17(7): 376-381. Web site. http://europepmc.org/abstract/med/3230611. Accessed February 17, 2017.

53. Wax MK, Yun KJ, Omar RA. Extramedullary plasmacytomas of the head and neck. *Otolaryngol Head Neck Surg.* 1993; 109(5): 877-885. doi: 10.1007/s00405-008-0613-0

54. Michalaki VJ, Hall J, Henk JM, Nutting CM, Harrington KJ. Definitive radiotherapy for extramedullary plasmacytomas of the head and neck. *Br J Radiol.* 2003; 76(910): 738-741. doi: 10.1259/bjr/54563070

55. Todd ID. Treatment of solitary plasmacytoma. *Clin Radiol.* 1965; 16: 395-399. doi: 10.1016/S0009-9260(65)80088-5

56. Novick WH, Shimo G, Ryder DR, Pirozynski WJ, Hazel JJ, Bouchard J. Malignant neoplasms of the nasopharynx. *Can Med Assoc J.* 1965; 93: 303-308.

57. Gromer RC, Duvall AJ 3rd. Plasmacytoma of the head and neck. *J Laryngol Otol.* 1973; 87(9): 861-872. doi: 10.1017/S0022215100077732

58. Patel TD, Vázquez A, Choudhary MM, Kam D, Baredes S, Eloy JA. Sinonasal extramedullary plasmacytoma: A population-based incidence and survival analysis. *Int Forum Allergy Rhinol.* 2015; 5(9): 862-869. doi: 10.1002/afir.21544

59. D’Aguillo C, Soni RS, Gordhan C, Liu JK, Baredes S, Eloy JA. Sinonasal extramedullary plasmacytoma: A systematic review of 175 patients. *Int Forum Allergy Rhinol.* 2014; 4(2): 156-63. doi: 10.1002/afir.21254

60. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. *Radiother Oncol.* 1999; 52(3): 245-249. doi: 10.1016/S0167-8140(99)00114-0

61. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome. *Int J Radiat Oncol Biol Phys.* 2001; 50(1): 113-120. doi: 10.1016/S0360-3016(00)15772-8

62. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. *Int J Radiat Oncol Biol Phys.* 2006; 64(4): 1013-1017. doi: 10.1016/j.ijrobp.2005.09.019

63. Creach KM, Foote RL, Neben-Wittich MA, Kyle RA. Radiotherapy for extramedullary plasmacytoma of the head and neck. *Int J Radiat Oncol Biol Phys.* 2009; 73(3): 789-794. doi: 10.1016/j.ijrobp.2008.04.077

64. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullaryplasmacytoma: Tumor occurrence and therapeutic concepts. *Cancer.* 1999; 85(11): 2305-2314. doi: 10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3

65. Sasaki S, Hashimoto K, Nakatsuka S, et al. Plasmablastic extramedullary plasmacytoma associated with Epstein-Barr virus arising in an immunocompetent patient with multiple myeloma. *Intern Med.* 2011; 50(21): 2615-2620.